Clinical Research Directory

Inclusion Criteria: * Patients ≥18 years of age with CLM undergoing elective hepatectomy with curative intent (primary colorectal primary cancer previously removed OR being removed at time of hepatectomy) after preoperative chemotherapy (i.e., FOLFOX/FOLFIRI +/- bevacizumab or panitumumab/cetuximab) from 07/01/2021 - 12/31/2023 * Must receive ≥ 4 cycles of preoperative chemotherapy Exclusion Criteria: * Patients with primary colorectal tumor that will remain in situ * Inability to undergo postoperative chemotherapy, or postoperative chemotherapy not planned a priori * Unwilling/unable to undergo blood draws for ctDNA, patient or provider-determined * Other active malignancies requiring treatment * Women who are pregnant